Compare BHR & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | ARMP |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 156.4M |
| IPO Year | 2013 | 1996 |
| Metric | BHR | ARMP |
|---|---|---|
| Price | $2.02 | $4.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 378.1K | 145.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $487,614,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | ★ 13.03 | N/A |
| 52 Week Low | $1.88 | $2.40 |
| 52 Week High | $3.19 | $14.98 |
| Indicator | BHR | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 41.00 | 47.49 |
| Support Level | $1.93 | $4.51 |
| Resistance Level | $2.61 | $5.60 |
| Average True Range (ATR) | 0.09 | 0.52 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 12.36 | 48.41 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.